Kronos Bio Inc (KRON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kronos Bio Inc (KRON) has a cash flow conversion efficiency ratio of -0.161x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.84 Million) by net assets ($79.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kronos Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Kronos Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Kronos Bio Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Kronos Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kronos Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Top High Image
TWO:3284
|
-0.004x |
|
Allegiant Gold Ltd
V:AUAU
|
-0.013x |
|
Qliro AB
ST:QLIRO
|
-0.156x |
|
FIT INVEST JSC
VN:FIT
|
0.269x |
|
Metair
JSE:MTA
|
-0.172x |
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
0.033x |
|
Instil Bio Inc.
NASDAQ:TIL
|
-0.062x |
|
Airmate Cayman International Co Ltd
TW:1626
|
0.007x |
Annual Cash Flow Conversion Efficiency for Kronos Bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kronos Bio Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Kronos Bio Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $87.58 Million | $-65.44 Million | -0.747x | -51.25% |
| 2023-12-31 | $159.08 Million | $-78.58 Million | -0.494x | -32.83% |
| 2022-12-31 | $244.50 Million | $-90.93 Million | -0.372x | -8.83% |
| 2021-12-31 | $345.10 Million | $-117.92 Million | -0.342x | -319.59% |
| 2020-12-31 | $465.52 Million | $-37.91 Million | -0.081x | -112.53% |
| 2019-12-31 | $-23.20 Million | $-15.08 Million | 0.650x | -26.37% |
| 2018-12-31 | $-7.30 Million | $-6.44 Million | 0.883x | -- |
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more